ponatinib,blinatumomab
amgen,astellas,takeda,otsuka,incyte
['ponatinib', 'leusm', 'cml', 'ph+ all', 'blinatumomab']
congress |#ash22| poster , presented the phase ii sub-study results of ponatinib + blinatumomab in pts with r/r ph+all(n=14) or cml-lbp(n=6), which proved effective and safe in both cohorts. a high cmr rate of 79% was observed in r/r ph+ all
#leusm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm